Nephrogen Analysis: $125K Raised
What is Nephrogen?
Nephrogen is a preclinical biotech company focused on developing gene therapies for life-threatening kidney diseases, particularly autosomal dominant polycystic kidney disease (ADPKD).
Employees
1
Founded
2020
Revenue
$5M
Product Features & Capabilities
- curative gene therapies for kidney diseases, targeting autosomal dominant polycystic kidney disease (ADPKD), non-invasive local delivery method, engineered AAV viruses with 100x better efficiency, personalized approach targeting PKD1 gene, rapid drug discovery platform leveraging computer vision and
How much Nephrogen raised
1: - $125K
January 1, 2020Lead Investor: Not specified
Market Focus
Nephrogen primarily focuses on the biotechnology industry, specifically developing curative gene therapies for life-threatening kidney diseases, with an emphasis on autosomal dominant polycystic kidney disease (ADPKD).
Competitors Overview
Nephrogen operates in the gene therapy market for kidney diseases, particularly focusing on autosomal dominant polycystic kidney disease (ADPKD). Its main competitors include:
- Otsuka Pharmaceutical Co., Ltd.: Known for its drug tolvaptan, which is approved for the treatment of ADPKD. Otsuka
Investors
- 2048 Ventures
- Contrary (San Francisco)
- Darwin (Munich)
- Lightspeed Venture Partners
- Phoenix Investment Club (San Francisco)
- StartX (Stanford-StartX Fund)
- Y Combinator
See something that needs updating? Suggest edits to this profile.